Skip to content

To study the vancomycin drug levels and its effect in patients in patients admitted to Pediatric Intensive Care Unit of Major hospital

Pharmacokinetics-Pharmacodynamics relationship of vancomycin in children with suspected or proven Gram-positive bacterial infection admitted to Pediatric intensive care unit of tertiary care hospital

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2016/01/006527
Enrollment
24
Registered
2016-01-14
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patients admitted to PICU with suspected or proven bacterial infection

Interventions

Intervention1: Vancomycin: Vancomycin is a glycopeptide antibiotic used treat the suspected or proven gram positive bacterial infection. 20mg/kg/dose every 8 hours. 1 vial (500mg) will be diluted in 5

Sponsors

Seth GSMC and KEM Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Voluntarily given written, signed, informed consent from legally acceptable representative and assent from patientâ??s aged >= 7 to 12 years before performing any screening procedures. 2. Either gender of aged 3 - 12 years and weight of >= 8 kg 3. Patients with suspected or proven Gram â?? positive bacterial infection 4. Patient receiving vancomycin therapy for at least 2 days

Exclusion criteria

Exclusion criteria: 1. Patients with hypersensitivity to vancomycin hydrochloride or any excipients of its formulation or other drugs 2. Participation in any investigational study within 30 days prior to screening. 3. Patients whose Creatinine clearance

Design outcomes

Primary

MeasureTime frame
TPharmacokinetics-Pharmacodynamics relationship of vancomycin in children with suspected or proven Gram-positive bacterial infection admitted to Pediatric intensive care unit of tertiary care hospitalTimepoint: 1

Secondary

MeasureTime frame
i. To assess the pharmacokinetics of intravenous vancomycin at steady state iii. To assess the association between AUC: MIC ratio of vancomycin with clinical outcome as assessed by survival or clinical cure. Timepoint: 1

Countries

India

Contacts

Public ContactNitin Mali

Seth GSMC and KEM Hospital

nitinbmali85@gmail.com02224133767

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026